The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V77958 | SARS-CoV-2 Mpro-IN-8 | SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral drug with anti-SARS-CoV-2 properties. | |
|
V54400 | SARS-CoV-2 Mpro-IN-9 | 2754370-99-3 | SARS-CoV-2 Mpro-IN-9 (compound c7) is a non-peptide, non-covalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM) with improved physicochemical, drug metabolism and pharmacokinetics Learn (DMPK) properties. |
|
V75483 | SARS-CoV-2 nsp14-IN-1 | 2816165-02-1 | SARS-CoV-2 nsp14-IN-1 (Compound 3) is a typical dual-substrate inhibitor of SARS-CoV-2 Nsp14 MTase, with an activity IC50 of 0.061 μM. |
|
V76077 | SARS-CoV-2 nsp14-IN-2 | 2816165-16-7 | SARS-CoV-2 nsp14-IN-2 is a potent inhibitor of SARS-CoV-2 Nsp14 methyltransferase with IC50 of 0.093 µM. |
|
V54372 | SARS-CoV-2 nsp14-IN-3 | 2920574-16-7 | SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor (blocker/antagonist) of SARS-CoV-2 Nsp14 N7-methyltransferase (IC50= 7 μM). |
|
V81364 | SARS-CoV-2 nsp14-IN-4 | SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor (blocker/antagonist) of SARS-CoV-2 nsp14 methyltransferase (IC50 is 19 nM). | |
|
V76086 | SARS-CoV-2 nsp3-IN-1 | 2892105-43-8 | SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor (antagonist) with IC50 of 6.1 μM. |
|
V54397 | SARS-CoV-2-IN-10 | 2722634-95-7 | SARS-CoV-2-IN-10 is a potent and non-toxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with IC50 and EC50 of 0.13 and 1.03 nM respectively. |
|
V54409 | SARS-CoV-2-IN-11 | 2722635-28-9 | SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with IC50 and EC50 of 0.17 and 1.45 nM, respectively. |
|
V77713 | SARS-CoV-2-IN-25 disodium | SARS-CoV-2-IN-25 (Compound CP026) disodium is a potent inhibitor of SARS-CoV-2 spike pseudoparticle transduction with IC50 of 1.6 μM. | |
|
V37548 | SARS-CoV-2-IN-31 | 1017691-52-9 | SARS-CoV-2-IN-31 is a potent COVID-19 inhibitor. |
|
V37544 | SARS-CoV-2-IN-32 | 96068-42-7 | SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. |
|
V37543 | SARS-CoV-2-IN-33 | 299919-79-2 | SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. |
|
V81366 | SARS-CoV-2-IN-34 | SARS-CoV-2-IN-34 (S-20-1) is a pan-coronavirus (CoV) fusion inhibitor (antagonist) with broad-spectrum inhibitory activity that can penetrate the BBB (blood-brain barrier). | |
|
V54404 | SARS-CoV-2-IN-35 | 2757763-47-4 | SARS-CoV-2-IN-35 is an orally bioactive SARS-CoV-2 M pro inhibitor (antagonist) with a Ki of 12.1 nM. |
|
V80058 | SARS-CoV-2-IN-36 | SARS-CoV-2-IN-36 is a potent inhibitor of SARS-CoV-2 Mpro (SARS-CoV) with IC50 of 2.37 μM and a Kd of 1.19 μM in an enzymatic assay. | |
|
V54429 | SARS-CoV-2-IN-38 | 2882823-27-8 | SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor (antagonist) with good oral bioavailability (F) in mice (F%=39.75%). |
|
V54396 | SARS-CoV-2-IN-39 | 2882823-03-0 | SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor (antagonist) with EC50 of 1 μM. |
|
V78846 | SARS-CoV-2-IN-40 | SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. | |
|
V54417 | SARS-CoV-2-IN-41 | 2920904-06-7 | SARS-CoV-2-IN-41 (compound 2) is a potent SARS-CoV-2 3CLpro inhibitor (antagonist) with IC50 of 0.022 µM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
